Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature by Hsu, P. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2014
Mantle cell lymphoma with in situ or mantle zone
growth pattern: a study of five cases and review of
literature
P. Hsu
Hofstra Northwell School of Medicine
T. Yang
Hofstra Northwell School of Medicine
S. Sheikh-Fayyaz
Hofstra Northwell School of Medicine
J. Brody
Hofstra Northwell School of Medicine
J. Bandovic
Northwell Health
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pathology Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Hsu P, Yang T, Sheikh-Fayyaz S, Brody J, Bandovic J, Roy S, Laser J, Kolitz J, Devoe C, Zhang X. Mantle cell lymphoma with in situ or
mantle zone growth pattern: a study of five cases and review of literature. . 2014 Jan 01; 7(3):Article 752 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/752. Free full text article.
Authors
P. Hsu, T. Yang, S. Sheikh-Fayyaz, J. Brody, J. Bandovic, S. Roy, J. Laser, J. E. Kolitz, C. Devoe, and X. Zhang
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/752
Int J Clin Exp Pathol 2014;7(3):1042-1050
www.ijcep.com /ISSN:1936-2625/IJCEP1312085
Original Article
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Abstract: We present two rare cases of in situ mantle cell lymphoma (“in situ MCL”) and three cases of MCL with 
mantle zone growth pattern (MCL-MZGP). The patients include four males and one female, with a median age of 
66 years (range, 52 to 86 years). Two present with isolated lymphadenopathy and three with multiple lymphade-
nopathy. At presentation, the complete blood count (CBC) and serum lactate dehydrogenase (LDH) are normal in 
all cases. Histologic examination reveals an in situ pattern in two cases and a mantle zone growth pattern in three 
cases. The staging bone marrow biopsies show minimal involvement by lymphoma in one case and no morphologic 
evidence of lymphoma in four cases. All cases are positive for cyclin D1, including two with typical MCL phenotype 
and three with CD5-negativity. Four out of five cases express kappa light chain. FISH study for t(11;14) is performed 
in three cases, of which one is positive and two are inconclusive. For four patients with a median follow-up of 38 
months, three are in clinical remission and one has persistent disease. In conclusion, the “in situ MCL” is associ-
ated with incidental finding, indolent clinical course and lower tumor burden. The predominant usage of kappa light 
chain and frequent CD5-negativity observed in our cases are unusual. We review the clinical and laboratory features 
of “in situ MCL” cases in the literature. 
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Introduction
Mantle cell lymphoma (MCL) comprises 3 to 
10% of non-Hodgkin lymphomas and has an 
aggressive clinical course with a median sur-
vival of 3 to 5 years [1]. MCL is characterized by 
t(11;14)(q13;q32) translocation involving the 
CCND1 and immunoglobulin heavy chain 
genes. This translocation results in overexpres-
sion of cyclin D1, which leads to dysregulation 
of the cell cycle and, combined with chromo-
somal instability and activation of cell survival 
mechanisms, contributes to the pathogenesis 
of MCL [2, 4]. MCL typically co-expresses B-cell 
antigens (CD19 and CD20) and CD5 and lacks 
CD23, with lambda light chain being more com-
monly used than kappa light chain. Three histo-
logical patterns have been recognized in lym-
phoid tissues: mantle zone, nodular and dif-
fuse. It is believed that the histological patterns 
reflect the natural process of disease progres-
sion. A larger minority of MCL shows mantle 
zone pattern that appears to be associated 
with a better prognosis [3]. On very rare occa-
sions, cyclin D1-positive cells are restricted to 
the mantle zones in a morphologically incon-
spicuous lymph node. This histologic pattern 
has been designated as “in situ MCL”, which is 
often an incidental finding and associated with 
indolent clinical behavior [12]. “In situ MCL” is 
considered as a very early stage of MCL or even 
a preneoplastic state. Due to its low frequency, 
the biological behaviors and clinical implica-
tions of “in situ MCL” remain unclear. Here, we 
present the clinicopathological features of five 
cases of MCL with in situ or MZGP pattern and 
also review the literature on “in situ MCL”.
Materials and methods
Case selection
We identify five cases of MCL with either “in situ 
MCL” or MCL-MZGP diagnosed in two tertiary 
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hospitals of the North Shore-Long Island Jewish 
Health System from 2008 to 2013. All cases 
are identified on the basis of the histologic and 
immunophenotypic features.
Histological and immunohistochemical studies
Paraffin-embedded tissue is available from the 
diagnostic biopsies. Immunohistochemical stu- 
dies are performed with a panel of pre-diluted 
antibodies including CD20 (Ventana), CD3 (Ven- 
tana), Cyclin D1 (Dako), CD5 (Ventana), CD10 
(Ventana), CD23 (Ventana), BCL-6 (Dako) and 
BCL-2 (Zymed). Staining is performed using 
automated immunostainer (Ventana Medical 
System, Tucson, AZ, USA).
Flow cytometric analysis
Cells are stained with a panel of fluorescence 
labeled monoclonal antibodies including CD3, 
CD4, CD5, CD7, CD8, CD10, CD19, CD20, 
CD23, FMC7, kappa and lambda. The cells are 
washed with PBS for three times and fixed in 
4% paraformadehyde PBS solution before anal-
ysis. Routine three-color flow cytometric analy-
sis is performed using FACSDiva software 
(Becton-Dickenson Biosciences, San Jose, Cali- 
fornia).
Fluorescence in situ hybridization study
Fluorescence in situ hybridization (FISH) analy-
sis is performed on tissue imprints using both 
LSI IGH/CCND1 dual-color, dual-fusion translo-
cation probe and LSI IGH dual-color, break-
apart probe (Abbott Molecular, Des Plains, IL) 
following the standard protocol.
Immunoglobulin variable gene analysis
Genomic DNA is extracted from formalin-fixed 
and paraffin embedded tissue sections (QIA- 
GEN GmbH, Hilden, Germany). PCR is per-
formed on the genomic DNAs using 5’ Ig heavy 
chain variable region leader primer and 3’ con-
stant region primer. The PCR products are used 
for IGHV gene mutation analysis. 
Results
Clinical features
Table 1 summarizes the clinical and laboratory 
features of the five cases. The patients include 
four males and one female, with a median age 
of 66 years (range, 52 to 86 years). Clinical his-
tory is remarkable for carcinoma in two patients 
and non-caseating granuloma in one patient. 
The remaining two patients have no significant 
past history. Two patients present with isolated 
lymphadenopathy and three with multiple 
lymphadenopathy. At presentation, the CBC 
and serum LDH are normal in all cases. There is 
no evidence of splenic or gastrointestinal sys-
tem involvement. The staging bone marrow 
biopsies show minimal involvement in one 
case, whereas no evidence of lymphoma is 
observed by morphology and cyclin D1 staining 
in the remaining cases. However, a minute 
monoclonal B-cell population is identified by 
flow cytometry in three of the last four cases. 
Four patients receive chemotherapy and one 
patient is newly diagnosed. The four patients 
who received treatment are still alive after a 
median follow-up of 38 months (range, 34 to 
48 months), with three in clinical remission and 
one with persistent disease. 
Histopathology and immunohistochemical 
studies
“In situ MCL”: In case 1 the lymph node is most-
ly replaced by non-necrotizing granulomas and 
only scattered lymphoid follicles, some contain-
ing reactive germinal centers, and small areas 
of T-zones are identified between the granulo-
mas (Figure 1A). In case 2 the lymph node 
biopsy shows architecture preservation with 
prominent paracortical hyperplasia, some folli-
cles with reactive germinal centers, and pres-
ence of sinuses (Figure 1B). In both cases, the 
mantle zones appear normal or only mildly 
expanded (Figure 1C and 1D). There is no defin-
itive morphologic evidence of lymphoprolifera-
tive disorder. However, flow cytometry per-
formed as part of routine lymphoma work up 
identify a monoclonal B-cell population in both 
cases. 
Immunohistochemical studies are subsequent-
ly performed on paraffin-embedded tissue sec-
tions. The germinal center cells show positive 
staining for CD20, BCL-6, and are negative for 
BCL-2. The mantle zone cells show positive 
staining for CD20, BCL-2 and cyclin D1 (Figure 
1E), and are negative for CD5 (Figure 1F). The 
cyclin D1-positive cells are confined to the man-
tle zones without mantle zone expansion. 
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MCL-MZGP: In case 4 and 5, the lymph nodes 
are partially effaced by crowded follicles con-
taining reactive germinal centers. The mantle 
zones are markedly expanded and focally fused 
between adjacent follicles. Occasional primary 
follicles are also noted. T-zones are present and 
sinuses are intact in some areas (Figure 2A, 2B 
and 2E).
Immunohistochemical studies are performed 
on paraffin-embedded tissue sections. The 
mantle zone cells reveal positive staining for 
CD20 and cyclin D1, and are negative for CD10 
and CD23. The neoplastic cells appear to be 
CD5 positive in case 5, but are negative in case 
4. The mantle zones are virtually replaced by 
cyclin D1 positive cells which focally extend into 
interfollicular regions (Figure 2C, 2D and 2F). 
The germinal centers appear positive for CD20, 
CD10 and bcl-6, and negative for bcl-2. The 
interfollicular regions comprise of predomi-
nantly T-cells.
Mixed “in situ” and MZGP pattern: In case 3, 
some follicles have normal mantle zones con-
sistent with in situ pattern whereas others 
show mantle zone expansion consistent with 
MZGP pattern (Figure 3A). The mantle zone 
cells show positive staining for CD20, CD5 and 
cyclin D1 (Figure 3B-D), and are negative for 
CD10 and CD23. 
Table 1. Clinical and laboratory features of five cases of MCL
Cases No. 1 No. 2 No. 3 No. 4 No. 5
Age 65 52 86 67 46
Sex Female Male Male Male Male
Clinical history Granuloma Vocal SCC Cancer No No
CBC
    WBC (X109/L) 6.3 9.0 5.6 6.9 6.4
    Hb (g/dL) 13.5 15.5 15.3 14.5 15.2
    Plt (X109/L) 219 188 248 247 198
LDH 146 200 189 196 214
Lymphadenopathy Single Single Multiple Multiple Multiple
Splenomegaly No No No No No
Site of Bx Cervical LN Cervical LN Cervical LN Axillary LN Axillary LN
Histology
    In situ MCL Yes Yes Yes
    MCL-MZGP Yes Yes Yes
BM involvement Minimal No* No No* No*
Immunophenotype
    Surface Igs kappa Kappa Kappa Kappa lambda
    CD19 + + + + +
    CD20 + + + + +
    CD5 - - + - +
    CD23 + (partial) - - - -
    CD38 + N/A + + +
    FMC-7 + (partial) + + N/A N/A
    cyclin D1 + + + + +
FISH for t(11;14) # # N/A + N/A
IGHV mutation Yes N/A N/A N/A N/A
Treatment Yes Yes No Yes Yes
Follow-up 38 38 2 48 34
Status AND AND Alive AWD AND
AND, alive without disease; AWD, alive with disease; Bx, biopsy; BM, bone marrow; FISH, fluorescence in situ hybridization; Hb, 
hemoglobin; Ig, immunoglobulin; IGHV, Ig heavy chain variable region; LN, lymph node; N/A, not applicable; Plt, platelet; SCC, 
squamous cell carcinoma; WBC, white blood cell. *No involvement by morphology and cyclin D1 staining, but flow cytometry 
shows a minute population of monoclonal B-cells. #In conclusive due to limited number of cells for analysis.
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Flow cytometry findings
In all the cases flow cytometric analysis is per-
formed in both lymph node and bone marrow 
specimens (Table 1). Two cases show classic 
MCL phenotype, whereas three cases are CD5-
negative, including both “in situ MCL” cases. 
Interestingly, four out of five cases express 
kappa light chain. Both CD38 and FMC-7 are 
positive in all the cases with data available for 
Figure 1. “In situ MCL” in lymph nodes. (A) H&E staining in case 1 reveals a reactive-appearing follicle with germinal 
center in a background of non-caseating granulomas (X100). (B) H&E staining in case 2 reveals a lymph node with 
multiple reactive-appearing follicles and prominent paracortical hyperplasia (X20). H&E higher power view of two 
reactive-appearing follicles with germinal centers and normal mantle zones (X200, C) and (X400, D). (E) Immunohis-
tochemical staining for cyclin D1 highlights scattered positive cells in mantle zones (X200). (F) CD5 (case 2) reveals 
negative staining in mantle zone cells and numerous T-cells in paracortical regions (X200).
Mantle cell lymphoma with low tumor load
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analysis. CD23 is partially expressed in one 
case.
FISH study and IGHV gene mutation analysis
In three cases we study the t(11;14) transloca-
tion by FISH using both dual-color, dual-fusion 
translocation probe and dual-color break-apart 
probe, of which one is positive, and two are 
inconclusive due to limited number of cells for 
analysis and both are “in situ MCL”. In addition, 
we have sufficient material to perform IGHV 
study using paraffin embedded sections in 
case 1, which shows a clonal B-cell population 
with evidence of somatic mutation of IGHV 
gene. 
Figure 2. MCL-MZGP in lymph nodes. H&E staining in case 5 (A, X20) and case 4 (B, X40) reveals numerous reactive-
appearing follicles with germinal centers and focally intact sinuses. Immunohistochemical staining for cyclin D1 
highlight expanded mantle zones in case 5 (C) and case 4 (D) (X40). (E) Higher power view of one reactive-appearing 
follicle with germinal centers and expanded mantle zones (H&E, X200). (F) Higher power view of cyclin D1 staining 
in one follicle (X200).
Mantle cell lymphoma with low tumor load
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Discussion
“In situ MCL” is very rare and only a small num-
ber of cases have been reported in literature 
[4-12]. A recent study that evaluates 1292 con-
secutive reactive lymph nodes from 131 
patients reveals no single case of “in situ MCL” 
[13]. Given its rarity, the biological behaviors 
and clinical implication of “in situ MCL” remain 
unclear. Two cases reported here show an in 
situ pattern in an otherwise reactive lymph 
node and are both incidental findings and have 
indolent clinical course, which fulfill the diag-
nostic criteria for “in situ MCL”. On the other 
hand, MCL-MZGP appears to have higher tumor 
burden at presentation than “in situ MCL”. 
However, we do not observe any difference 
between the two groups with regard to overall 
survival. All four patients who receive treatment 
are still alive at the time of this submission, but 
one patient with MCL-MZGP has persistent dis-
ease. Whether “in situ MCL” represents a pre-
cursor lesion or early colonization by MCL is still 
being debated. Studies have shown that 
patients with an incidentally diagnosed “in situ 
MCL” do not progress to overt disease, irre-
spective of whether treatment has been admin-
istrated or not. Furthermore, in some cases “in 
situ MCL” is retrospectively identified years 
before the discovery of overt MCL [12, 14]. 
Interestingly, our case 3 shows a mixture of in 
situ pattern and mantle zone growth pattern in 
a single lymph node, which illustrates the dis-
ease progression. These findings support the 
notion that “in situ MCL” may represent a pre-
cursor or even a preneoplastic lesion. On the 
other hand, in situ lesions have also been iden-
tified in some patients with a previous history 
of MCL who develop overt MCL soon after the 
discovery of in situ lesion. One study suggests 
that these cases should be considered as early 
colonization by MCL rather than a precursor 
lesion [13]. It is important to make such a dis-
tinction because the managements for these 
two groups are different. 
Figure 3. Histopathology and immunohistochemical studies in case 3. (A) H&E staining reveals numerous reactive-
appearing follicles (X40). (B) immunohistochemical staining for cyclin D1 reveals a mixture of MCL-MZGP and “in situ 
MCL” (X40). Higher power view of Cyclin D1 staining for “in situ MCL” (C) and MCL-MZGP (D) (X200). 
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In reviewing of the literature we identify twenty-
one “in situ MCL” cases (Table 2) [4-12]. The 
clinical and laboratory features of the twenty-
one cases plus two current cases are reviewed. 
The median age at presentation is 65 years 
(range, 29 to 84 years), with no significant sex 
predilection. Most patients are asymptomatic 
and present with a single enlarged lymph node. 
Extranodal involvement is observed in some 
patients. Splenic involvement is very rare 
though bone marrow or/and peripheral blood 
involvement is observed in a subset of patients. 
The in situ lesion is usually an incidental finding 
and most patients are managed with a “watch 
and wait” approach. The vast majority of 
patients are alive without disease progression 
after a median follow up of three years. 
MCL is characteristically CD5-positive, but a 
small subset has been reportedly CD5 nega-
tive, which appears to be associated with indo-
lent clinical course and nodal involvement [15, 
16]. Based on CD5 expression, twenty-two of 
the twenty-three cases can be divided into two 
subgroups: (1) CD5 negative “in situ MCL”. 
There are eleven patients with a male to female 
ratio of 5 to 6. The median age is 59 years 
(range, 29 to 84 years). Most patients (8 of 11 
cases) have a clinical history of cancer or 
inflammatory diseases. All but one patient have 
nodal involvement. Four patients receive either 
chemotherapy or radiation therapy. Three 
cases with IGHV mutation status available for 
analysis show evidence of somatic hypermuta-
tion. (2) CD5 positive “in situ MCL”. There are 
eleven cases in this group as well, with a medi-
an age of 72 years (range, 42 to 82 years). The 
male to female ratio is 6 to 5. Of the eleven 
patients, six have extranodal involvement, four 
have multiple lymphadenopathy, and seven are 
associated with other low grade B-cell lympho-
mas. Seven out of ten patients receive treat-
ments. In summary, it appears that CD5 nega-
tivity in “in situ MCL” is associated with younger 
age, history of cancer or inflammatory diseas-
es, nodal involvement, and lower chance to 
receive treatment, whereas CD5 expression is 
associated with older age, frequent extranodal 
Table 2. Clinical and laboratory features of twenty-one reported in situ MCL cases
Case Age/ Sex Site of Bx
Other 
sites BM PB Management
F/U  
(yr) Status CD5
Comosite
lymphoma
Other
pathology
1 29/F Inguinal LN LNs Yes Yes W&W 19.5 AWD - - -
2 72/F Submandibular LN No Yes Yes W&W 12 AWD - - Granuloma
3 42/F Cervical LN No No No W&W 1 AND - - Breast Ca
4 84/F Spleen No N/A No W&W 1.4 Died - FL Colon Ca
5 42/M Supclaviculal LN No No N/A RT 1.7 AND - - Castleman disease
6 59/M Cervical LN No No No W&W 5 AND - - Thyroid ca
7 65/F LN No Yes N/A Chemo 0.5 AND - - Granuloma
8 40/M Cervical LN No N/A N/A N/A N/A N/A - FL -
9 70/M Cervical LN No N/A No W&W 4  MCL - - -
10 70/F Nasopharynx No No No W&W 3 AND + - -
11 58/M Intestine No Yes No Chemo 1.4 AND + - -
12 42/F LNs, GIT LNs Yes No Chemo 6 AND + - -
13 78/F Lacrimal gland No No No N/A N/A N/A + eMZL -
14 72/F Cervical No N/A No RT 2 AND + NMZL Breast Ca
15 82/M Oropharynx LT N/A Yes W&W 3 AWD + CLL/SLL -
16 82/M LN No No No Chemo 1.5 AND + CLL/SLL -
17 80/M Inguinal LN LNs Yes Yes Chemo N/A N/A + CLL/SLL -
18 80/M Cervical LN No No No Chemo 1.5 Died + FL -
19 65/F Intramammal LN LNs No No Chemo 5 AND + FL -
20 65/M Appendix No N/A N/A W&W 4 MCL + - -
21 68/M Mediastinal LN No N/A N/A W&W 1 AND N/A - -
AND, alive with no disease; AWD, alive with disease; Bx, biopsy; BM, bone marrow; Ca, carcinoma; Chemo, chemotherapy; CLL/SLL, chronic lym-
phocytic leukemia/small lymphocytic lymphoma; eMZL, extranodal marginal zone lymphoma; F, female; FL, follicular lymphoma; F/U, follow up; GIT, 
gastrointestinal; LN, lymph node; LT, lymphoid tissue; M, male; N/A, not applicable; NMZL, nodal marginal zone lymphoma; PB, peripheral blood; RT, 
radiation therapy; W&W, watch and wait; yr, year.
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involvement, frequent association with other 
low-grade B-cell lymphomas, and higher chance 
to receive treatment. However, the two groups 
do not show any difference in overall survival. 
Proposed cells of origin for MCL include memo-
ry and naïve splenic marginal zone cells, periph-
eral memory B-cells, and lymphoid follicle man-
tle cells [17]. “In situ MCL” is believed to be 
related to naïve cells of primary follicle cells 
and of the inner mantle zone of the secondary 
follicles. Gene expression analysis reveals that 
MCL with high mutation rates in IGHV gene 
demonstrates a gene signature similar to mem-
ory B-cells while MCL with low mutation rates 
resembles naïve B-cells [18]. Three of the CD5-
negative MCL cases show somatic hypermuta-
tion, suggesting that at least a subset of “in situ 
MCL” may originate from memory B-cells. 
Further study may help our understanding of 
the cell origin and pathogenesis of “in situ 
MCL”. 
MCL exhibits predominant expression of lamb-
da light chain, which is different from other lym-
phomas. The IGHV gene repertoire in MCL is 
remarkably biased, with four genes (IGHV3-21, 
IGHV4-34, IGHV1-8, and IGHV3-23) collectively 
accounting for almost half of the cases [19]. 
Immunogenetic studies have demonstrated the 
following features in MCL: (i) remarkable biases 
in the IGHV gene repertoire; (ii) restricted asso-
ciations of certain V, D and J genes, leading to 
the formation of stereotyped B-cell receptors 
(BCRs); and (iii) very precisely targeted somatic 
hypermutation (SHM). The bias is very pro-
nounced among IGHV3-21 MCL cases that 
almost exclusively express lambda light chains 
and display highly restricted use of the IGLV3-
19 gene. These findings suggest that an anti-
gen-driven process may be implicated in the 
pathogenesis of MCL, at least for subsets of 
cases [20]. As opposed to lambda predomi-
nance seen in MCL, our cases show predomi-
nant usage of kappa light chain, which is also 
observed in a small cohort of indolent leukemic 
MCL [21]. All these cases appear to have a rela-
tively indolent clinical course. Whether they 
represent a distinct functional group is still 
unclear at this time. Additional study is needed 
to address this issue. 
In summary, we add two cases to a rare collec-
tion of “in situ MCL” that is often incidental find-
ing and associated with indolent clinical course. 
The kappa predominance and frequent CD5-
negativity observed in our cases are unusual 
for MCL, which suggests a possible antigen-
driven origin in these cases. In reviewing of the 
literature, we have shown that “in situ MCL” 
appears to be heterogeneous. 
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